{"id":55718,"date":"2023-04-12T11:03:15","date_gmt":"2023-04-12T09:03:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-distribution-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-to-2023-featuring-abbott-eli-lilly-gsk-novartis-hundreds-more-researchandmarkets-com\/"},"modified":"2023-04-12T11:03:15","modified_gmt":"2023-04-12T09:03:15","slug":"global-distribution-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-to-2023-featuring-abbott-eli-lilly-gsk-novartis-hundreds-more-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-distribution-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-to-2023-featuring-abbott-eli-lilly-gsk-novartis-hundreds-more-researchandmarkets-com\/","title":{"rendered":"Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 to 2023: Featuring Abbott, Eli Lilly, GSK, Novartis & Hundreds More – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 to 2023”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a><\/p>\n

\nThe Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.<\/p>\n

\nFully revised and updated, the report provides details of distribution agreements from 2016 to 2023.<\/p>\n

\nThe report provides a detailed understanding and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.<\/p>\n

\nUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.<\/p>\n

\nThis report contains a comprehensive listing of over 2,200 distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.<\/p>\n

\nThe initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.<\/p>\n

\nChapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.<\/p>\n

\nChapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.<\/p>\n

\nChapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.<\/p>\n

\nChapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.<\/p>\n

\nThe appendices to the report includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.<\/p>\n

\nThe report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.<\/p>\n

\nThe report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.<\/p>\n

\nIn conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.<\/p>\n

\nKey benefits<\/strong><\/p>\n

\nGlobal Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides the reader with the following key benefits:<\/strong><\/p>\n